Lonza Group stock holds steady as analysts lift targets
Published on 08/18/2026 at 14:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Lonza Group stock is holding a valuation snapshot of US$726.30, with a market cap of CHF 40.23 billion and a recent 52-week range between US$595.85 and US$1,007.48. The latest visible consensus view in the same data set shows an average 1-year target of US$822.50, which sits 13.25% above the current quote.
Valuation stays elevated
The company is still priced on a premium multiple, with a PE ratio of 54.9x in the same market-data view. That gap between the current quote and the average target gives investors a concrete reference point for how far the market is already discounting growth.
On the home market, the shares were last shown at 565.60 CHF, down 0.1% on the session, while the intraday low reached 563.80 CHF and turnover stood at 9,817 shares. The stock was only 4.49% below its 52-week high of 591.00 CHF, set on July 10, 2026.
Trading range in view
The same session data also placed the 52-week low at 454.60 CHF on March 23, 2026, which leaves the stock 19.63% above that floor. For chart watchers, that keeps the recent pullback in context without breaking the broader range.
Business backdrop
MarketScreener describes Lonza Group AG as one of the world leaders in contract development and manufacturing for pharmaceutical and biotechnology products. That positioning matters because investors tend to track the shares against order flow, capacity use and pharma outsourcing demand rather than a single product cycle.
Lonza's product base
UC-II is one of Lonza Capsugel's best-known consumer-health brands, and it has been highlighted by the company in recent marketing activity. It gives the group exposure beyond drug manufacturing, even though the stock is still mainly valued on its pharma-services franchise.
Recent trading levels
For now, the cleanest market read is simple: the Swiss line at 565.60 CHF and the US quote at US$726.30 both leave the name close to recent highs, while the consensus target of US$822.50 still implies room if execution stays intact.
More on Lonza Group stock
Investor Relations
Fact box
Company: Lonza Group AG
ISIN: CH0013841017
Ticker: LONN
Exchange: SIX Swiss Exchange
Price (as of August 18, 2026): 565.60 CHF
Market cap: CHF 40.23 billion
Sector / Industry: Health Care / Life Sciences Tools & Services
Index membership: SMI
Next earnings date: September 4, 2026
